CDC Tops 1 Million Voluntary Participants in Traveler Genomic Surveillance Program

Translate to Spanish or other 102 languages!

Through voluntary and anonymous sample collection from arriving international travelers at select U.S. airports, the program provides early insight into emerging pathogens and variants before they spread broadly within the United States. Image for illustration purposes
Through voluntary and anonymous sample collection from arriving international travelers at select U.S. airports, the program provides early insight into emerging pathogens and variants before they spread broadly within the United States. Image for illustration purposes
- Advertisement -

The Centers for Disease Control and Prevention (CDC) today announced that its Traveler-Based Genomic Surveillance (TGS) program has surpassed one million voluntary participants, marking a significant milestone in the United States’ ability to detect and respond to emerging public health threats at our borders.

TGS is one of many tools the United States uses to strengthen disease surveillance and protect the American people. Through voluntary and anonymous sample collection from arriving international travelers at select U.S. airports, the program provides early insight into emerging pathogens and variants before they spread broadly within the United States.

“The United States is the world’s leading authority in public health,” said HHS Deputy Secretary and Acting CDC Director Jim O’Neill. “The broad participation of travelers enhances our ability to safeguard the nation using tools that are developed, operated, and governed here at home without reliance on unaccountable global bureaucracies.” 

- Advertisement -

The TGS program operates through public-private partnerships with organizations including Ginkgo Biosecurity and XWell, as well as cooperation from select U.S. airports. These partnerships enable CDC to generate rapid biosurveillance data when testing and sequencing information may be limited elsewhere in the world.

Launched in 2021, TGS monitors for communicable diseases among arriving international travelers, with a focus on early detection of emerging variants of seasonal respiratory viruses and other pathogens of public health concern. For example, the program reported the first two detections of influenza H3N2 subclade K to public repositories seven days before the next publicly reported sequence—demonstrating the value of early, U.S.-based surveillance.

Participation in the program is voluntary and anonymous. In addition to nasal samples from travelers, CDC has analyzed more than 2,600 airplane wastewater samples as part of its broader biosurveillance efforts.

As President Trump has made clear, the United States will remain the global leader in public health by strengthening domestic capabilities, advancing health innovation, and ensuring rapid response to infectious disease threats. Programs like TGS reflect that commitment by enhancing national biosecurity.

- Advertisement -

Additional information about current TGS data can be found here.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Heart Valve Designed to Grow with Children

The U.S. Food and Drug Administration today approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.

STHS Clinics Surgeon Dr. Miguel Rodriguez Earns Prestigious National Recognition

Miguel Rodriguez, DO, FACS, a general, robotic and bariatric surgeon with STHS Clinics, has been inducted as a Fellow of the American College of Surgeons (ACS), earning the prestigious FACS designation.

AACT Now Launches Rally the Vote Across Rio Grande Valley

The Advocacy Alliance Center of Texas, or AACT Now, launched its Rally the Vote initiative Thursday, bringing together community organizations and regional leaders to expand access to nonpartisan voter information across the Rio Grande Valley.

Healthcare Alliance Recognizes Texas Oncology Investment in Valley Cancer Care

Maritza Gonzalez, founder and director of the Texas Healthcare Alliance Chamber of Commerce, recognized Texas Oncology’s continued investment in Rio Grande Valley cancer care during the Sept. 29 grand opening of the Texas Oncology McAllen West clinic.
- Advertisement -